retatrutide clinical data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA VisualAbstract: Retatrutide reduces body weight

People seeking respiratory support NAC's longest history of use outside the hospital setting is in respiratory health

The newer binders, sodium zirconium cyclosilicate, and patiromer, facilitate optimization of RAAS blockage therapy and have supportive evidence

Most major insurers cover semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) only after step-therapy protocolsmeaning you must try and fail cheaper alternatives first

It is on the WADA Prohibited List in category S2 Peptide Hormones and Their Releasing Factors, and also banned by professional sport leagues like MLB, but curiously it is not on the NFL list

Weight Loss: While weight loss can be a desirable outcome for many individuals with type 2 diabetes, excessive weight loss associated with GLP-1 medications may be problematic for some patients, especially those who are already at a healthy weight or at risk of malnutrition